Acute Porphyria Drug Database

J07AG01 - Haemophilus Influenzae B, Purified Antigen Conjugated
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the hemophilus influenzae B, purified antigen conjugated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Haemophilus influenzae type b polysaccaride conjugated to tetanus carrier protein.
Therapeutic characteristics
The hemophilus influenza B vaccine is indicated for the prevention of invasive disease caused by Haemophilus influenzae type b in children from 2 months through 5 years of age. It is administered by intramuscular injections, in infants usually according to a three or four dose schedule.
Metabolism and pharmacokinetics
The hemophilus influenza B vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. Norwegian medicines agency. Summary of Product Characteristics (SPC). Act-Hib. #1859

Similar drugs
Explore alternative drugs in similar therapeutic classes J07A / J07AG or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙